Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Malcolm Ranson
Sign up to set email alerts
412
Publications
11,709
Citation Statements Received
5,722
Citation Statements Given
How they've been cited
17,407
370
11,295
44
How they cite others
9,064
282
5,404
36
Affiliations
The Christie Hospital
,
The Christie NHS Foundation Trust
Publications
Order By: Most citations
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Cross
1
,
Ashton
2
,
Ghiorghiu
3
et al.
2014
Abstract
Show
2,325
38
1,837
1
Get access via publisher
Add to collection
Cite
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Janne
1
,
Yang
2
,
Kim
3
et al.
2015
N Engl J Med
Abstract
Show
2,166
46
1,629
5
Get access via publisher
Add to collection
Cite
Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer
Krebs
1
,
Szczepaniak‐Sloane
2
,
Priest
3
et al.
2011
JCO
Abstract
Show
876
47
705
10
Get access via publisher
Add to collection
Cite
Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches
Krebs
1
,
Hou
2
,
Szczepaniak‐Sloane
3
et al.
2012
Journal of Thoracic Oncology
Abstract
Show
471
27
459
2
Get access via publisher
Add to collection
Cite
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
Baselga
1
,
Rischin
2
,
Ranson
3
et al.
2002
JCO
Abstract
Show
815
15
450
2
Get access via publisher
Add to collection
Cite
ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial
Ranson
1
,
Hammond
2
,
Ferry
3
et al.
2002
JCO
Abstract
Show
742
9
405
0
Get access via publisher
Add to collection
Cite
Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer
Hou
1
,
Krebs
2
,
Ward
3
et al.
2011
The American Journal of Pathology
Abstract
Show
445
13
381
1
Get access via publisher
Add to collection
Cite
Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
Rudin
1
,
Hann
2
,
Garon
3
et al.
2012
Abstract
Show
581
7
384
1
Get access via publisher
Add to collection
Cite
1
2